TSUNO-GROUP
31.1.2024 08:16:27 CET | Business Wire | Press release
Tsuno Group Co., Ltd., headquartered in Katsuragi-cho, Ito-gun, Wakayama, and led by President: Fumi Tsuno and Matsumoto Trading Co., Ltd., headquartered in Chuo-ku, Tokyo, with CEO Shunsuke Matsumoto have successfully developed a new sunscreen formulation with Ferulic Acid. Ferulic Acid is a rare natural plant-derived UV absorber that has been difficult in stability and solubility at the high concentrations of ferulic acid.
For ferulic acid
Tsuno Group was the first in the world to successfully produce large amounts of ferulic acid, a polyphenol, from rice bran. Ferulic acid possesses strong antioxidant properties and has been recognized for its potential to prevent Alzheimer's disease, diabetes mellitus, and high cholesterol. It can also be used as a raw material for producing natural vanillin, a vanilla flavoring. In cosmetics, it inhibits melanin production by blocking tyrosinase activity and has anti-inflammatory, antimicrobial, and antioxidant properties. Therefore, it has been used as an active ingredient in a variety of cosmetic products.
“We, as a leading company in rice & bran chemistry in the world, have been developing a number of functional products with tremendous efforts through accumulating technologies, have also researched their safe levels and effects to be well accepted in pharma, food, feed and cosmetic industries. Now we have launched a technology of using ferulic acid from rice bran as a natural antioxidant and UV absorber, which is the first innovation ever in the world. We are confident that you shall discover this product as unique and impactful to contribute not only to the human health and beauty but the circular economy for the world.” —— Fumi Tsuno, President of Tsuno Group Co., Ltd.
UV absorption effect of ferulic acid
Ethylhexyl methoxycinnamate (EHMC), a petrochemical UV filter, is most widely used in sunscreen applications. However, recent studies have shown its negative impact on the aquatic environment, including coral bleaching. Ferulic acid, a naturally derived sunscreen ingredient from rice, absorbs UV rays in a similar range of the spectrum as octyl methoxycinnamate (OMC). This promising characteristic makes it a potential eco-friendly alternative to EHMC. Amidst growing global concerns about environmental sustainability, ferulic acid's potential as a natural and effective sunscreen ingredient is likely to gain increased recognition. It holds significant potential for application in a wide range of cosmetic products throughout Japan.
Development of high stability formulation of UV-care products with high concentration of Ferulic Acid
Gaining recognition for its UV-absorbing properties, ferulic acid, a rare natural plant-derived ingredient, presents challenges in solubility and stability at the high concentrations for sunscreen formulations. To overcome these hurdles, Matsumoto Trading has dedicated research and development, pioneering an innovative technology utilizing a high concentration of ferulic acid in a solid stick formulation. This novel formulation has been developed with SPF50+ and PA++ (in vitro) containing only ferulic acid, a natural UV absorber extracted from rice bran. This unique formulation eliminates the need for other commonly used UV protective ingredients, while maintaining high sun protection effectiveness. Patent pending.
About Tsuno Rice Fine Chemicals Co., Ltd.
Tsuno Rice Fine Chemicals manufactures various ingredients from by-products generated in the process of refining rice bran oil, and they can be used for pharmaceutical, cosmetic, functional foods, food additives, feedstock, and industrial chemicals. In addition, we are also engaged in the manufacture of cosmetics under our own brand that incorporate these ingredients.
Business Profile of Tsuno Group Co., Ltd.
We are promoting the advanced and effective use of rice bran, a symbol of health and beauty that has been popular since ancient times. We are developing three businesses: the Rice Bran Oil Production Business, the Fine Chemicals Business, and the Oleo Chemical Business.
Established: February 1, 1947
Representative Director and President Fumi Tsuno
URL : https://www.tsuno.co.jp/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130923907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
